Cheng Chee | Biological Therapy/Immunotherapy Chemotherapy Gene Therapy Pain Management Targeted Therapy

Cheng Chee, MD

Medical Oncologist

Conditions Treated

Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

specialties & services

Biological Therapy/Immunotherapy Chemotherapy Gene Therapy Pain Management Targeted Therapy

Hospitals & Clinics

Bio & Insurance Information

Insurance Accepted

Aetna Choice POS II Aetna HMO First Health PPO

Education & Training

Royal Free Hospital and University College London Medical School

Medical School

Mayo School of Graduate Medical Education

Residency

Mayo School of Graduate Medical Education

Fellowship

Board Certifications

American Board of Internal Medicine

American Board of Internal Medicine - Hematology

American Board of Internal Medicine - Oncology

Medical License

MN State Medical License Active through 2012

OH State Medical License Active through 2015

Hospitals & Clinics

Publications

Dr. Cheng Chee has contributed to 3 publications.

Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas.

Chee CE Krishnamurthi S Nock CJ Meropol NJ Gibbons J Fu P Bokar J Teston L O'Brien T Gudena V Reese A Bergman M Saltzman J Wright JJ Dowlati A Brell J; Oncologist. 2013 .

Targeted therapeutic agents for colorectal cancer.

Chee, C.E., Sinicrope, F.A.; Gastroenterol Clin North Am. 2010 Sep

Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival.

Larsen, J.T., Chee, C.E., Lust, J.A., Greipp, P.R., Rajkumar, S.V.; Blood. 2011 Sep 8.